These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 22986402)

  • 1. ACP Journal Club. Glargine did not reduce CV events more than standard care in patients with dysglycemia.
    Lader E
    Ann Intern Med; 2012 Sep; 157(6):JC3-10, JC3-11. PubMed ID: 22986402
    [No Abstract]   [Full Text] [Related]  

  • 2. ACP Journal Club. Daily n-3 fatty acid supplements did not reduce CV events in high-risk patients with dysglycemia.
    Lader E
    Ann Intern Med; 2012 Sep; 157(6):JC3-11. PubMed ID: 22986403
    [No Abstract]   [Full Text] [Related]  

  • 3. ACP Journal Club. Nateglinide did not reduce diabetes or CV events in patients with impaired glucose tolerance and CV risk factors.
    Farkouh M
    Ann Intern Med; 2010 Jun; 152(12):JC6-10. PubMed ID: 20547892
    [No Abstract]   [Full Text] [Related]  

  • 4. ACP Journal Club. Daily multivitamin supplements did not reduce risk for major CV events over > 10 years in men.
    Fairfield KM
    Ann Intern Med; 2013 Feb; 158(4):JC8. PubMed ID: 23420255
    [No Abstract]   [Full Text] [Related]  

  • 5. ACP Journal Club: Review: Low BP targets do not reduce mortality or CV events in hypertension.
    McAlister FA
    Ann Intern Med; 2009 Nov; 151(10):JC5-6-7. PubMed ID: 19920264
    [No Abstract]   [Full Text] [Related]  

  • 6. ACP Journal Club. Review: Aspirin does not reduce CV events but may reduce nonfatal stroke in peripheral artery disease.
    Mukherjee D
    Ann Intern Med; 2009 Sep; 151(6):JC3-5, JC3-4. PubMed ID: 19755351
    [No Abstract]   [Full Text] [Related]  

  • 7. ACP Journal Club. Adding prompt revascularization to medical therapy did not reduce mortality or CV events in patients with type 2 diabetes and CAD.
    Poirier P
    Ann Intern Med; 2009 Oct; 151(8):JC4-5. PubMed ID: 19841443
    [No Abstract]   [Full Text] [Related]  

  • 8. ACP Journal Club. Valsartan reduced diabetes but not CV events in patients with impaired glucose tolerance and CV risk factors.
    Ann Intern Med; 2010 Jun; 152(12):JC6-9. PubMed ID: 20547903
    [No Abstract]   [Full Text] [Related]  

  • 9. ACP journal club. Intensive glucose control increased mortality and did not prevent CV events compared with standard glucose control in type 2 diabetes.
    Grubina R; Smith SA
    Ann Intern Med; 2011 May; 154(10):JC5-02. PubMed ID: 21576520
    [No Abstract]   [Full Text] [Related]  

  • 10. ACP Journal Club. Review: Statins reduce mortality and cardiovascular (CV) morbidity in patients with low CV risk.
    Muñoz D; Granger CB
    Ann Intern Med; 2012 Apr; 156(8):JC4-07. PubMed ID: 22508747
    [No Abstract]   [Full Text] [Related]  

  • 11. ACP Journal Club. Intensive and standard glucose control did not differ for major CV events or death in poorly controlled type 2 diabetes.
    Booth GL
    Ann Intern Med; 2009 Mar; 150(6):JC3-8. PubMed ID: 19306490
    [No Abstract]   [Full Text] [Related]  

  • 12. ACP Journal Club. Intensive glucose control did not reduce a composite of microvascular events more than standard control in type 2 diabetes.
    Aron DC; Pogach LM
    Ann Intern Med; 2010 Nov; 153(10):JC5-9. PubMed ID: 21079216
    [No Abstract]   [Full Text] [Related]  

  • 13. ACP Journal Club. Use of ≥ 1 antihypertensive drug at bedtime reduced CV events more than use of all drugs in the morning in CKD.
    Sinha AD; Agarwal R
    Ann Intern Med; 2012 Jun; 156(12):JC6-8. PubMed ID: 22711109
    [No Abstract]   [Full Text] [Related]  

  • 14. ACP Journal Club: review: varenicline for tobacco cessation does not increase CV serious adverse events.
    Krebs P; Sherman SE
    Ann Intern Med; 2012 Aug; 157(4):JC2-2. PubMed ID: 22910956
    [No Abstract]   [Full Text] [Related]  

  • 15. ACP Journal Club. Adding omeprazole to clopidogrel reduced GI events and did not increase CV events.
    Chow CK
    Ann Intern Med; 2011 Mar; 154(6):JC3-7. PubMed ID: 21403070
    [No Abstract]   [Full Text] [Related]  

  • 16. ACP Journal Club. Review: statins decrease mortality and major CV events in adults with CKD not receiving dialysis.
    Ramesh Prasad GV
    Ann Intern Med; 2012 Nov; 157(10):JC5-4. PubMed ID: 23165680
    [No Abstract]   [Full Text] [Related]  

  • 17. ACP Journal Club: metformin reduced CV events compared with glipizide in patients with type 2 diabetes and CAD.
    Tanner M
    Ann Intern Med; 2013 Apr; 158(8):JC4. PubMed ID: 23588769
    [No Abstract]   [Full Text] [Related]  

  • 18. ACP Journal Club. Adding procalcitonin-guided therapy to standard care did not reduce mortality in critically ill patients.
    Sacks HS
    Ann Intern Med; 2012 Feb; 156(4):JC2-06. PubMed ID: 22351732
    [No Abstract]   [Full Text] [Related]  

  • 19. ACP Journal Club. Review: lipid-lowering drugs decrease all-cause and cardiac mortality and CV events in CKD.
    Ramesh Prasad GV
    Ann Intern Med; 2012 Nov; 157(10):JC5-5. PubMed ID: 23165681
    [No Abstract]   [Full Text] [Related]  

  • 20. ACP Journal Club. Review: ACE-Is or ARBs reduce adverse CV outcomes regardless of baseline systolic blood pressure.
    Singh V
    Ann Intern Med; 2012 Jul; 157(2):JC2-8. PubMed ID: 22801699
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.